Wave Life Sciences Ltd. - WVE STOCK NEWS

IMPACT

SENTIMENT

08/03/2023 07:30 AM

WVE : Nasdaq

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

IMPACT

SENTIMENT

07/27/2023 08:30 AM

WVE : Nasdaq

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

IMPACT

SENTIMENT

06/26/2023 08:30 AM

WVE : Nasdaq

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

IMPACT

SENTIMENT

05/23/2023 07:30 AM

WVE : Nasdaq

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

IMPACT

SENTIMENT

05/16/2023 08:30 AM

WVE : Nasdaq

Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

IMPACT

SENTIMENT

05/03/2023 07:30 AM

WVE : Nasdaq

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

IMPACT

SENTIMENT

04/26/2023 08:30 AM

WVE : Nasdaq

Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023

IMPACT

SENTIMENT

04/20/2023 08:30 AM

WVE : Nasdaq

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

IMPACT

SENTIMENT

03/29/2023 08:00 AM

WVE : Nasdaq

Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days

IMPACT

SENTIMENT

03/22/2023 07:30 AM

WVE : Nasdaq

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

#3558 Ranked by Market Cap

N/A Ranked by Dividends

WVE Stock Data

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country Singapore

City 7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.